Menu
Search
|

Menu

Close
X

Rhythm Pharmaceuticals Inc RYTM.OQ (NASDAQ Stock Exchange Global Market)

27.61 USD
+1.55 (+5.95%)
As of Feb 23
chart
Previous Close 26.06
Open 26.18
Volume 9,183
3m Avg Volume 42,003
Today’s High 27.61
Today’s Low 26.18
52 Week High 33.80
52 Week Low 21.38
Shares Outstanding (mil) 27.13
Market Capitalization (mil) 685.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.050
FY16
-1.906
FY15
-0.397
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
18.14
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

David Meeker
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Keith Gottesdiener
President, Chief Executive Officer, Director, Since 2017
Salary: $476,500.00
Bonus: $85,770.00
Hunter Smith
Chief Financial Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Lex H.T. Van der Ploeg
Chief Scientific Officer, Since 2011
Salary: --
Bonus: --
Nithya Desikan
Chief Commercial Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

500 Boylston St Fl 11
BOSTON   MA   02116-3740

Phone: +1857.2644280

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

SPONSORED STORIES